We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy (C3R)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 19, 2010
Last Update Posted: April 19, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mashhad University of Medical Sciences
Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.

Condition Intervention
Bullous Keratopathy Radiation: ultraviolet-A

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking

Resource links provided by NLM:

Further study details as provided by Mashhad University of Medical Sciences:

Enrollment: 20
Study Start Date: November 2008
Study Completion Date: September 2009
Intervention Details:
    Radiation: ultraviolet-A
    Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with bollous keratopathy

Exclusion Criteria:

  • corneal scarring or contemporary eye disease affecting VA were excluded.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT01106274     History of Changes
Other Study ID Numbers: MUMS-88191
First Submitted: April 16, 2010
First Posted: April 19, 2010
Last Update Posted: April 19, 2010
Last Verified: October 2008

Additional relevant MeSH terms:
Corneal Edema
Corneal Diseases
Eye Diseases
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents